Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0K4WQ)

Drug Name

PF-07261271 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Inflammatory bowel disease	DD72	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Vascular endothelial cell growth inhibitor (TNFSF15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PRA023	DMUY4VV	Crohn disease	DD70	Phase 2	[3]
TEV-48574	DMHWN63	Crohn disease	DD70	Phase 2	[4]
------------------------------------------------------------------------------------

Drug(s) Targeting Interleukin-12 beta (IL12B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[5]
ABT-874	DMYHSO2	Plaque psoriasis	EA90.0	Phase 3	[6]
EGEN-001	DM6L5TR	Fallopian tube cancer	2C74	Phase 2	[7]
SFV IL-12 gene therapy	DMVIWNK	Breast cancer	2C60-2C65	Phase 2	[8]
Ad-IL-12 DNA therapeutic	DMB19IO	Melanoma	2C30	Phase 1/2	[9]
NHS-IL 12	DMU6CQ7	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-12 beta (IL12B)	TTGW72V	IL12B_HUMAN	Not Available	[2]
Vascular endothelial cell growth inhibitor (TNFSF15)	TTEST6I	TNF15_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05536440) A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO CONTROLLED, DOSE ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE INTRAVENOUS AND MULTIPLE SUBCUTANEOUS AND INTRAVENOUS DOSES OF PF-07261271 IN HEALTHY PARTICIPANTS. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Pfizer
3	Clinical pipeline report, company report or official report of Prometheus Biosciences
4	Clinical pipeline report, company report or official report of Teva Pharmaceutical
5	A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005.
6	Briakinumab for the treatment of plaque psoriasis.BioDrugs.2012 Feb 1;26(1):9-20.
7	National Cancer Institute Drug Dictionary (drug id 454593).
8	Clinical pipeline report, company report or official report of Trademarkia.
9	National Cancer Institute Drug Dictionary (drug id 710508).
10	The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget. 2014 Apr 15;5(7):1869-84.